Oncology Exchange: Current Treatment Strategies for Chronic Myelogenous Leukemia

Credit Area For Credit: Register/Login     View Activity As Guest

Release Date: Sep 17, 2013          Expiration Date: Sep 17, 2014



By clicking the View/Register Button you are agreeing that you have read and understood the information on this page.



This program is part of a series of associated Oncology Exchange programs; Click Here for information.

Program Description


The treatment algorithm for chronic myelogenous leukemia (CML) has evolved significantly with newly approved drugs and emerging data from ongoing clinical studies of novel treatment regimens in CML. Community clinicians are constantly challenged to stay up to date with recent advances in treatment, monitoring, and management of adverse events in CML.

Oncology Exchange: Current Treatment Strategies for Chronic Myelogenous Leukemia will use clinical case scenarios to provide guidance on the optimal treatment algorithms for the management of CML, while also exploring common issues faced by community clinicians involved in the treatment of CML patients.


Faculty



JORGE CORTES, MD
D.B. Lane Cancer Research
Distinguished Professor for Leukemia Research
Deputy Chairman, Section Chief of AML and CML
Department of Leukemia
University of Texas MD Anderson Cancer Center
Houston, TX

Read Biography

MOSHE TALPAZ, MD
Alexander J. Trotman Professor
Associate Director for Translational Research
Comprehensive Cancer Center
University of Michigan Hospital and Health System
Ann Arbor, MI

Read Biography


Target Audience


This activity is intended for community-based hematologists/oncologists and other health care professionals involved in the care of patients with chronic myelogenous leukemia.


Educational Objectives


At the conclusion of this activity, participants should be able to demonstrate the ability to:

  • Identify changes in therapeutic indications and clinical practice guidelines for CML
  • Understand practical aspects of monitoring responses in patients with CML
  • Identify the role of BCR-ABL mutations in making treatment decisions in CML
  • Review emerging data from ongoing studies of novel treatment regimens and evaluate ongoing clinical trials of investigational agents

Accreditation


This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the Potomac Center for Medical Education and Rockpointe Oncology. The Potomac Center for Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.


Designation Statement


The Potomac Center for Medical Education designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

For questions regarding this activity, please email contact@rockpointe-pcme.com.


Disclosure Statement


Potomac Center for Medical Education (PCME) adheres to the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.

All persons in a position to control the content of a continuing medical education program sponsored by the Potomac Center for Medical Education are required to disclose any relevant financial relationships with any commercial interest to PCME as well as to learners. All conflicts are identified and resolved by PCME in accordance with the Standards for Commercial Support in advance of delivery of the activity to learners.

The content of this activity was vetted by an external medical reviewer to assure objectivity and that the activity is free of commercial bias.

The faculty/steering committee reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:

Jorge Cortes, MD: Consultant:Ariad, Pfizer, Teva; Speaker: Ariad, Bristol-Myers Squibb, Novartis, Pfizer, Teva

Moshe Talpaz, MD: Speaker:Ariad, Novartis

Non-faculty Content Contributors:
Non-faculty content contributors and/or reviewers reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:

Latha Shivakumar, PhD, CCMEP; Blair St. Amand; Jay Katz, CCMEP; CME Peer Review: Nothing to disclose


FDA Disclosure


The contents of some CME activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.


System Requirements


In order to view this presentation, your computer must have audio capabilities (working speakers or headphones) and must have an Adobe Flash Player. The Adobe Flash Player can be downloaded here.

Instructions for Participants and Obtaining CME Credit


There is no fee for this activity. To receive credit, participants must take the pre-test, view this CME activity in its entirety, and then complete the post-test and evaluation. To complete the evaluation online, choose the best answer to each question. The estimated time for completion of this activity is 1 hour and 15 minutes. To receive their certificates, participants must demonstrate mastery of the presented material via the post-test.


Jointly Sponsored By



Supported By


Supported by an educational grant from:


By clicking the View/Register Button you are agreeing that you have read and understood the information on this page.